Medication fills for weight loss drugs such as Zepbound and Wegovy rose sharply this year, despite high out-of-pocket costs for patients, according to a Dec. 5 analysis from GoodRx.
GLP-1s
Should employers, patients, or insurers bear the largest share of an annual $411 billion cost?
Amgen's experimental GLP-1 drug, MariTide, resulted in an average 20% reduction in body weight in a 52-week phase 2 study, the company said Nov. 26.
The White House is pitching broader coverage of weight loss drugs for millions of Americans on Medicare and Medicaid.
The battle over who should provide obesity and diabetes drugs like Ozempic and Wegovy has reached a critical point, as manufacturers and compounding pharmacies clash over the demand of these medications, NPR reported Nov. 20.
Advertisement
Researchers estimate that 136.8 million adults in the U.S. are eligible for semaglutide, the generic for Novo Nordisk's Ozempic, Wegovy and Rybelsus.
A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder.
The ever-rising popularity of GLP-1 medications is reshaping the landscape of bariatric surgeries — but experts say patients could be overlooking key factors when choosing between the two weight loss treatments.
Telehealth companies selling low-cost, compounded versions of popular weight-loss drugs, including Ozempic and Wegovy, are drawing increased interest from employers, Bloomberg reported Oct. 29.
Between 2022 and 2023, prescriptions for GLP-1 drugs soared 132.6% while bariatric surgery rates fell 25.6%, according to a new study from researchers at Boston-based Harvard Medical School and Brigham and Women's Hospital.